1996
Bryostatin 1 activates splenic lymphocytes and induces sustained depletion of splenocyte protein kinase C activity in vivo after a single intravenous administration
Bear H, McFadden A, Kostuchenko P, Lipshy K, Hamad G, Turner A, Roberts J, Carr M, Carr S, Grant S. Bryostatin 1 activates splenic lymphocytes and induces sustained depletion of splenocyte protein kinase C activity in vivo after a single intravenous administration. Anti-Cancer Drugs 1996, 7: 299-306. PMID: 8792004, DOI: 10.1097/00001813-199605000-00010.Peer-Reviewed Original ResearchConceptsBryostatin 1Normal murine spleen cellsT-cell activation marker CD69PKC activityActivation marker CD69Single bolus injectionEarly lymphocyte activationSingle intravenous administrationAnti-tumor effectsNormal host tissuesCell surface phenotypeProtein kinase CMurine spleen cellsPlasma levels resultsRegulate protein kinase CAnti-cancer agentsControl miceMarked splenomegalyBolus injectionIntravenous administrationC57BI/6 miceSpleen cellsSplenocyte proliferationSplenic lymphocytesSurface phenotype
1984
Efficacy and toxicity of 4-(2-sulfonatoethylthio)-cyclophosphamide cyclohexylamine salt (ASTA Z 7557, INN mafosfamide) after intraperitoneal administration to mice
Roberts J, Hacker M, Newman R, McCormack J, Krakoff I. Efficacy and toxicity of 4-(2-sulfonatoethylthio)-cyclophosphamide cyclohexylamine salt (ASTA Z 7557, INN mafosfamide) after intraperitoneal administration to mice. Investigational New Drugs 1984, 2: 215-220. PMID: 6469517, DOI: 10.1007/bf00232354.Peer-Reviewed Original ResearchConceptsBladder toxicityIntraperitoneal administrationAcute bladder toxicityPhosphoramide mustardAZ therapyHepatic fibrosisIntravenous administrationLocal toxicityTherapeutic indexMurine systemAdministrationCyclophosphamide analoguesFurther studiesSpontaneous activationAssociated riskToxicityCyclohexylamine saltFibrosisTherapyMice
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply